Serono chronicles

Serono chronicles

Selected events tracked against Serono's weekly stock price since the company listed on the NYSE in 2000. 1/27/00 - Exclusively licenses recombinant leukemia inhibitory factor (LIF) from Amrad (now Zenyth Therapeutics) for development in reproductive health. The product was discontinued.A. 7/27/00 - Raises $989.9M in rights offering and lists on the NYSEB. 10/17/00 - SEO and British Biotech (now part of Vernalis) agree to develop and commercialize British Biotech's metalloenzyme inhibitors to treat inflammatory diseases. An MMP-12 inhibitor is now in Phase I testing for multiple sclerosis. C. 10/23/00 - Acquires exclusive worldwide rights to

Read the full 960 word article

How to gain access

Continue reading with a
two-week free trial.